Biocon Launches Biosimilar Yesafili in US
Biocon Ltd. announced the commercial launch of Yesafili™ (aflibercept-jbvf), a biosimilar to Regeneron's Eylea® 2 mg, in the United States on August 3, 2026. This marks a significant step in expanding global access to biosimilar aflibercept for patients with ophthalmology conditions. Yesafili™ has received U.S. FDA approval and an interchangeable designation, allowing for pharmacy-level substitution. The launch targets the substantial U.S. market for age-related macular degeneration and other serious eye conditions, with U.S. sales of aflibercept reaching approximately $5.89 billion in 2023. This move strengthens Biocon's presence in the ophthalmology sector and aims to improve patient access to life-changing treatments.
Key Highlights
- Biocon launched Yesafili™, a biosimilar aflibercept, in the United States.
- Yesafili™ is an FDA-approved interchangeable biosimilar to Eylea® 2 mg.
- The launch targets the significant U.S. market for eye conditions.
- This expands global availability of biosimilar aflibercept.
- The U.S. aflibercept market was valued at $5.89 billion in 2023.
Price Impact
More from BIOCON